Welcome
New Home-Mid Content
WELCOME
The King's Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to the diagnosis and treatment of hypercoagulable conditions.
We are a designated Haemophilia Centre and were the first National Venous Thromboembolism (VTE) Exemplar Centre, reflecting our national leadership in the prevention and treatment of VTE. Our clinical trials unit works in partnership with industry to develop new treatments for VTE prevention and treatment.
THE FIRST REGISTRY
With the next generation of oral anticoagulants entering clinical practice, the FIRST registry will provide an important data tool to increase knowledge and improve the quality of care of patients with VTE.
King's Thrombosis Centre COVID-19 Research
Clinicians and researchers in the King’s Thrombosis Centre are completing a number of research studies relating to the COVID-19 pandemic.
Click here to view the latest publications from our centre, relating to this.
Click here to view the BBC interview with Prof Roopen Arya on thrombosis in COVID-19.
VTE EXEMPLAR CENTRE NETWORK WEBSITE
After being hosted at the King's Thrombosis Centre website since its launch in 2007, the website is now managed as part of the National VTE prevention Programme at NHS England. Click here to access the site.
Latest News
-
Anticoagulation news items. Weeks commencing 3rd and 10th January 2022
Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex CirculationAnalysis (n=71,683) found standard-dose DOACs linked…
-
Anticoagulation news items. Weeks commencing 6th, 13th and 20th December 2021
Dabigatran etexilate (Pradaxa®) recommended for use within NHS Wales for venous thromboembolism (VTE) treatment and prevention in paediatric patients All Wales Medicines Strategy GroupDabigatran etexilate (Pradaxa®) hard capsules are recommended…
-
Anticoagulation news items. Weeks commencing 22nd and 29th November 2021
Mechanism suggested for development of rare blood clots with AstraZeneca covid 19 vaccine Science AdvancesThis rare syndrome resembling heparin-induced thrombocytopenia (HIT), has been observed with ChAdOx1 (AZ) vaccine. Computational simulation…
